Clinical Trials Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jul 21, 2015; 21(27): 8398-8407
Published online Jul 21, 2015. doi: 10.3748/wjg.v21.i27.8398
Table 5 Correlations between SLITRK3 expression and clinicopathological factors in 417 gastrointestinal stromal tumor patients
Clinicopathological factors1SLITRK3 expression
Number of patientsχ2P value2
LowHigh
GenderMale1001232240.0011.000
Female85104189
Age (yr) ≤ 60991212200.0001.000
> 6087106193
Gastrointestinal bleedingNo1531603137.7220.006
Yes3367100
Primary tumor siteStomach12010622624.730< 0.0013
Small bowel3488122
Colon14721
Others182644
Predominant cell typeSpindle1261442702.5520.279
Epithelioid262753
Mixed345690
Primary tumor size ≤ 5 cm1168319927.260< 0.0013
> 5 cm70144214
Mitotic index ≤ 5/50 HPF15714930618.763< 0.0013
> 5/50 HPF2978107
NIH stageVery low risk2833153.340< 0.0013
Low risk8767154
Intermediate risk254166
High risk46116162